$15.4 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 104 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 57.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AABA | Buy | ALTABA INC | $1,967,494,000 | -3.8% | 28,362,317 | +2.7% | 12.80% | -16.8% |
| CELG | Buy | CELGENE CORP | $1,427,736,000 | +79.5% | 15,445,000 | +83.2% | 9.29% | +55.3% |
| SPY | Buy | SPDR S&P 500 ETF TRput | $1,068,718,000 | +21.4% | 3,647,500 | +17.0% | 6.95% | +5.0% |
| RHT | Buy | RED HAT INC | $963,735,000 | +58.4% | 5,132,800 | +54.1% | 6.27% | +37.0% |
| APC | New | ANADARKO PETE CORP | $738,410,000 | – | 10,465,000 | +100.0% | 4.80% | – |
| WCG | Buy | WELLCARE HEALTH PLANS INC | $634,281,000 | +319.9% | 2,225,000 | +297.3% | 4.12% | +263.1% |
| WAB | Buy | WABTEC CORP | $471,346,000 | +2.4% | 6,568,373 | +5.2% | 3.07% | -11.4% |
| IQV | Buy | IQVIA HLDGS INC | $414,963,000 | +33.7% | 2,579,011 | +19.5% | 2.70% | +15.6% |
| ARRY | Buy | ARRAY BIOPHARMA INC | $393,805,000 | +193.7% | 8,500,000 | +54.5% | 2.56% | +154.1% |
| FIS | Buy | FIDELITY NATL INFORMATION SV | $348,735,000 | +45.1% | 2,842,640 | +33.8% | 2.27% | +25.5% |
| ANTM | Buy | ANTHEM INC | $296,321,000 | +25.2% | 1,050,000 | +27.3% | 1.93% | +8.2% |
| GD | Buy | GENERAL DYNAMICS CORP | $242,769,000 | +32.6% | 1,335,214 | +23.5% | 1.58% | +14.7% |
| SHW | Buy | SHERWIN WILLIAMS CO | $213,425,000 | +29.0% | 465,699 | +21.2% | 1.39% | +11.6% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $177,331,000 | +0.4% | 1,540,000 | +2.7% | 1.15% | -13.2% |
| AZN | Buy | ASTRAZENECA PLCsponsored adr | $169,248,000 | +7.8% | 4,100,000 | +5.5% | 1.10% | -6.8% |
| AGN | New | ALLERGAN PLC | $167,430,000 | – | 1,000,000 | +100.0% | 1.09% | – |
| CI | Buy | CIGNA CORP NEW | $165,428,000 | +8.9% | 1,050,000 | +11.1% | 1.08% | -5.9% |
| MYOK | Buy | MYOKARDIA INC | $100,280,000 | -1.1% | 2,000,000 | +2.5% | 0.65% | -14.5% |
| ZAYO | New | ZAYO GROUP HLDGS INC | $92,806,000 | – | 2,820,000 | +100.0% | 0.60% | – |
| BABA | Buy | ALIBABA GROUP HLDG LTDsponsored ads | $84,725,000 | +11.9% | 500,000 | +20.5% | 0.55% | -3.2% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $82,408,000 | +22.1% | 4,250,000 | +30.8% | 0.54% | +5.7% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $81,005,000 | -9.8% | 960,000 | +2.1% | 0.53% | -21.9% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $79,816,000 | +70.8% | 1,100,000 | +120.0% | 0.52% | +47.9% |
| GWR | New | GENESEE & WYO INCcl a | $77,500,000 | – | 775,000 | +100.0% | 0.50% | – |
| FGEN | Buy | FIBROGEN INC | $76,806,000 | +54.3% | 1,700,000 | +85.7% | 0.50% | +33.7% |
| NVCR | Buy | NOVOCURE LTD | $75,876,000 | +50.0% | 1,200,000 | +14.3% | 0.49% | +29.7% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $75,480,000 | +17.7% | 800,000 | +6.7% | 0.49% | +1.9% |
| S | Buy | SPRINT CORPORATION | $70,135,000 | +680.7% | 10,675,000 | +571.4% | 0.46% | +570.6% |
| GRFS | Buy | GRIFOLS S Asp adr rep b nvt | $64,990,000 | +10.4% | 3,080,083 | +5.3% | 0.42% | -4.5% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $53,000,000 | +50.4% | 2,000,000 | +4.1% | 0.34% | +30.2% |
| CVS | Buy | CVS HEALTH CORP | $44,818,000 | +33.0% | 822,500 | +31.6% | 0.29% | +14.6% |
| FDC | New | FIRST DATA CORP NEW | $38,575,000 | – | 1,425,000 | +100.0% | 0.25% | – |
| ZYME | Buy | ZYMEWORKS INC | $38,642,000 | +51.6% | 1,756,470 | +11.5% | 0.25% | +30.7% |
| PGNX | Buy | PROGENICS PHARMACEUTICALS IN | $34,203,000 | +75.5% | 5,543,386 | +32.0% | 0.22% | +51.0% |
| TMUS | New | T MOBILE US INC | $31,567,000 | – | 425,780 | +100.0% | 0.20% | – |
| FOXA | Buy | FOX CORP | $30,646,000 | +17.7% | 836,400 | +17.9% | 0.20% | +1.5% |
| BPL | New | BUCKEYE PARTNERS L Punit ltd partn | $29,550,000 | – | 719,857 | +100.0% | 0.19% | – |
| QTNT | New | QUOTIENT LTD | $23,375,000 | – | 2,500,000 | +100.0% | 0.15% | – |
| ZEAL | Buy | ZEALAND PHARMA A Ssponsored adr | $21,550,000 | +33.5% | 1,000,000 | +5.4% | 0.14% | +15.7% |
| NVTA | Buy | INVITAE CORP | $21,150,000 | +201.0% | 900,000 | +200.0% | 0.14% | +160.4% |
| CARA | New | CARA THERAPEUTICS INC | $20,454,000 | – | 951,326 | +100.0% | 0.13% | – |
| CCXI | Buy | CHEMOCENTRYX INC | $18,600,000 | -10.7% | 2,000,000 | +33.3% | 0.12% | -22.9% |
| AVRO | Buy | AVROBIO INC | $16,848,000 | -15.1% | 1,036,147 | +15.1% | 0.11% | -26.2% |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $10,600,000 | – | 1,000,000 | +100.0% | 0.07% | – |
| VCYT | New | VERACYTE INC | $9,979,000 | – | 350,000 | +100.0% | 0.06% | – |
| PHAS | New | PHASEBIO PHARMACEUTICALS INC | $9,931,000 | – | 756,961 | +100.0% | 0.06% | – |
| TWST | New | TWIST BIOSCIENCE CORP | $8,908,000 | – | 307,055 | +100.0% | 0.06% | – |
| SVRA | Buy | SAVARA INC | $8,236,000 | -53.9% | 3,475,000 | +43.3% | 0.05% | -59.7% |
| QURE | New | UNIQURE NV | $7,815,000 | – | 100,000 | +100.0% | 0.05% | – |
| MIST | New | MILESTONE PHARMACEUTICALS IN | $6,788,000 | – | 250,000 | +100.0% | 0.04% | – |
| New | SOLARCITY CORPnote 1.625%11/0 | $5,304,000 | – | 5,500,000 | +100.0% | 0.03% | – | |
| PSNL | New | PERSONALIS INC | $5,021,000 | – | 184,932 | +100.0% | 0.03% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $2,873,000 | – | 150,000 | +100.0% | 0.02% | – |
| ADPT | New | ADAPTIVE BIOTECHNOLOGIES COR | $1,208,000 | – | 25,000 | +100.0% | 0.01% | – |
| OXY | New | OCCIDENTAL PETE CORP | $1,006,000 | – | 20,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| GRIFOLS S A | 33 | Q4 2021 | 0.9% |
| ALPHABET INC | 32 | Q3 2023 | 4.2% |
| SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
| VISA INC | 30 | Q3 2023 | 2.9% |
| WABTEC CORP | 27 | Q3 2023 | 3.6% |
| EXELIXIS INC | 27 | Q3 2023 | 2.8% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
| SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
| Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
| Solid Power, Inc. | February 11, 2022 | ? | ? |
| Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-15 |
| 13F-HR/A | 2024-05-15 |
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.